32978291|t|Anti-SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome: Studies in 8 stuporous and comatose patients.
32978291|a|OBJECTIVE: To investigate the pathophysiologic mechanism of encephalopathy and prolonged comatose or stuporous state in severally ill patients with coronavirus disease 2019 (COVID-19). METHODS: Eight COVID-19 patients with signs of encephalopathy were tested for antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the serum and CSF using a Food and Drug Administration-approved and independently validated ELISA. Blood-brain barrier (BBB) integrity and immunoglobulin G (IgG) intrathecal synthesis were further tested using albumin and IgG indices. The CSF was also tested for autoimmune encephalitis antibodies and 14-3-3, a marker of ongoing neurodegeneration. RESULTS: All patients had anti-SARS-CoV-2 antibodies in their CSF, and 4 of 8 patients had high titers, comparable to high serum values. One patient had anti-SARS-CoV-2 IgG intrathecal synthesis, and 3 others had disruption of the blood-brain barrier. The CSF in 4 patients was positive for 14-3-3-protein suggesting ongoing neurodegeneration. In all patients, the CSF was negative for autoimmune encephalitis antibodies and SARS-CoV-2 by PCR. None of the patients, apart from persistent encephalopathic signs, had any focal neurologic signs or history or specific neurologic disease. CONCLUSIONS: High-titer anti-SARS-CoV-2 antibodies were detected in the CSF of comatose or encephalopathic patients demonstrating intrathecal IgG synthesis or BBB disruption. A disrupted BBB may facilitate the entry of cytokines and inflammatory mediators into the CNS enhancing neuroinflammation and neurodegeneration. The observations highlight the need for prospective CSF studies to determine the pathogenic role of anti-SARS-CoV-2 antibodies and identify early therapeutic interventions.
32978291	5	15	SARS-CoV-2	Species	2697049
32978291	51	70	barrier dysfunction	Disease	MESH:C536830
32978291	111	133	stuporous and comatose	Disease	MESH:D053608
32978291	134	142	patients	Species	9606
32978291	204	218	encephalopathy	Disease	MESH:D001927
32978291	233	244	comatose or	Disease	MESH:D003128
32978291	245	260	stuporous state	Disease	MESH:D053608
32978291	278	286	patients	Species	9606
32978291	292	316	coronavirus disease 2019	Disease	MESH:D000086382
32978291	318	326	COVID-19	Disease	MESH:D000086382
32978291	344	352	COVID-19	Disease	MESH:D000086382
32978291	353	361	patients	Species	9606
32978291	376	390	encephalopathy	Disease	MESH:D001927
32978291	421	468	severe acute respiratory syndrome coronavirus 2	Species	2697049
32978291	470	480	SARS-CoV-2	Species	2697049
32978291	695	702	albumin	Gene	213
32978291	748	771	autoimmune encephalitis	Disease	MESH:D020274
32978291	787	793	14-3-3	Gene	10971
32978291	815	832	neurodegeneration	Disease	MESH:D019636
32978291	847	855	patients	Species	9606
32978291	865	875	SARS-CoV-2	Species	2697049
32978291	912	920	patients	Species	9606
32978291	975	982	patient	Species	9606
32978291	992	1002	SARS-CoV-2	Species	2697049
32978291	1047	1057	disruption	Disease	MESH:D019958
32978291	1099	1107	patients	Species	9606
32978291	1159	1176	neurodegeneration	Disease	MESH:D019636
32978291	1185	1193	patients	Species	9606
32978291	1220	1243	autoimmune encephalitis	Disease	MESH:D020274
32978291	1259	1269	SARS-CoV-2	Species	2697049
32978291	1290	1298	patients	Species	9606
32978291	1322	1337	encephalopathic	Disease	
32978291	1399	1417	neurologic disease	Disease	MESH:D020271
32978291	1448	1458	SARS-CoV-2	Species	2697049
32978291	1498	1509	comatose or	Disease	MESH:D003128
32978291	1510	1525	encephalopathic	Disease	
32978291	1526	1534	patients	Species	9606
32978291	1582	1592	disruption	Disease	MESH:D019958
32978291	1652	1664	inflammatory	Disease	MESH:D007249
32978291	1698	1715	neuroinflammation	Disease	MESH:D000090862
32978291	1720	1737	neurodegeneration	Disease	MESH:D019636
32978291	1844	1854	SARS-CoV-2	Species	2697049
32978291	Association	MESH:D019636	10971

